Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116012 · ClinicalTrials.gov registry record · Phase 2
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
A Phase 2 study, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT00116012 is a Phase 2 study that has completed, run by ARCA Biopharma. The registered enrollment target is 300 participants.
The verdict
NCT00116012, a Phase 2 study, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The primary focus of this study is to explore the safety of a range of doses of rNAPc2 in subjects who are managed in hospitals that most typically practice an early invasive strategy (catheterization during the index admission). After completion of the ascending dose-ranging part of the trial and review of these data by the Data and Safety Monitoring Board (DSMB), the maximum tolerated dose of rNAPc2 will be studied in single-arm, open-label panels (approximately 25 subjects each) of rNAPc2 with descending doses of unfractionated heparin (UFH).
Interventions
- DRUG rNAPc2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116012
The ClinicalTrials.gov registry entry for NCT00116012 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rNAPc2 is the first listed.
NCT00116012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116012 about?
NCT00116012 is a clinical study titled "Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32". The primary focus of this study is to explore the safety of a range of doses of rNAPc2 in subjects who are managed in hospitals that most typically practice an early invasive strategy (catheterization during the index admission). After completion of the ascending dose-ranging part of the trial and r...
What is the current status of trial NCT00116012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2005-06.
What interventions are being tested in trial NCT00116012?
The interventions under investigation include: rNAPc2 (DRUG).
Who is sponsoring clinical trial NCT00116012?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.